Evidence map›Paper›PMID 41212420›Full record

ArticleNeurochemical research2025

Chronic Combined Oral Methylphenidate and Fluoxetine Increases Inflammation in Somatosensory and Mesolimbic Brain Regions.

Julianna Roeser, Huy Lu, Abigail M Lantry, Caleigh Hoerner, George Lagamjis, Shannon Klein, Rania Ahmed, Igor Elman, Albert Pinhasov, Ken Blum and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Julianna RoeserBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, 14068, USA.
Huy LuBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, 14068, USA.
Abigail M LantryBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, 14068, USA.
Caleigh HoernerBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, 14068, USA.
George LagamjisBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, 14068, USA.
Shannon KleinBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, 14068, USA.
Rania AhmedDepartment of Psychology, City University of New York, Queens, NY, USA.
Igor ElmanCambridge Health Alliance, Harvard Medical School, Cambridge, MA, USA.
Albert PinhasovDepartment of Molecular Biology, Adelson School of Medicine, Ariel University, Ariel, Israel.
Ken BlumDivision of Addiction Research & Education, Center for Sports, Exercise & Mental Health, Western University of the Health Sciences, Pomona, CA, 91766, USA.
Michael HadjiargyrouDepartment of Biological and Chemical Sciences, New York Institute of Technology, Old Westbury, NY, USA.
David E KomatsuDepartment of Orthopaedics and Rehabilitation, Stony Brook University, Stony Brook, NY, USA.
Panayotis K ThanosBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Clinical Research Institute on Addictions, Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, 14068, USA. thanos@buffalo.edu.

Funding

Serotonin receptors that potentiate addiction-related behavioral and molecular effects induced by methylphenidate plus SSRI exposureR01DA046794 · NIDA · ROSALIND FRANKLIN UNIV OF MEDICINE & SCI · PI BOLANOS, CARLOS A., STEINER, HEINZ · 2019 to 2023
$1.7M
Skeletal Effects of MethylphenidateR01HD070888 · NICHD · STATE UNIVERSITY NEW YORK STONY BROOK · PI KOMATSU, DAVID E · 2013 to 2017
$1.6M
NICHD NIH HHS R01 HD070888NIDA NIH HHS R01 DA046794
6 · The paper itself

Abstract

Methylphenidate (MP) is commonly prescribed to treat attention deficit hyperactivity disorder (ADHD). ADHD and depression are often comorbid, leading to simultaneous use of serotonin reuptake inhibitors (SSRIs), such as Fluoxetine (FLX). Previous studies have shown MP increases microglial activation, which has been linked to neuroinflammation, but little is known about these two medications in combination. To address this gap in our knowledge, 3-week-old male Sprague Dawley rats were randomly assigned into four groups receiving either water, MP, FLX, or MP + FLX orally using a previously established dosing regimen. After four weeks of treatment the animal's brains were collected for in vitro [

Indexed as

BrainFluoxetineInflammationMethylphenidateSelective Serotonin Reuptake InhibitorsSomatosensory CortexAdministration, OralAnimalsMaleRatsRats, Sprague-DawleyFluoxetineMethylphenidateSelective Serotonin Reuptake InhibitorsAutoradiographyFluoxetineMethylphenidateMicrogliaNeuroinflammationSerotonin reuptake inhibitors

Identifiers

PMID41212420
PMCPMC12602612

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.